Nicotinamide as a treatment option of Age-Related Macular Degeneration
Open Access
- 1 January 2017
- journal article
- Published by Heighten Science Publications Corporation
- Vol. 1 (1), 063-065
- https://doi.org/10.29328/journal.jsctt.1001006
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Complement in the fundamental processes of the cellMolecular Immunology, 2017
- Complement Factor H Inhibits CD47-Mediated Resolution of InflammationImmunity, 2017
- Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular DegenerationCell Stem Cell, 2017
- Age-related macular degeneration associated polymorphism rs10490924 in ARMS2 results in deficiency of a complement activatorJournal of Neuroinflammation, 2017
- Complement activation and choriocapillaris loss in early AMD: Implications for pathophysiology and therapyProgress in Retinal and Eye Research, 2014
- Intracellular Complement Activation Sustains T Cell Homeostasis and Mediates Effector DifferentiationImmunity, 2013
- Abundant Lipid and Protein Components of DrusenPLOS ONE, 2010
- The Vitamin Nicotinamide: Translating Nutrition into Clinical CareMolecules, 2009
- Nicotinamide Restores Cognition in Alzheimer's Disease Transgenic Mice via a Mechanism Involving Sirtuin Inhibition and Selective Reduction of Thr231-PhosphotauJournal of Neuroscience, 2008
- Proteomic Approaches to Understanding Age-Related Macular DegenerationAdvances in Experimental Medicine and Biology, 2003